Discontinuation report REPATHA
| Report ID | 223420 |
| Drug Identification Number | 02459779 |
| Brand name | REPATHA |
| Common or Proper name | evolocumab injection |
| Company Name | AMGEN CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | EVOLOCUMAB |
| Strength(s) | 120MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | 420 mg / 3.5 mL (AMD) |
| ATC code | C10AX |
| ATC description | LIPID MODIFYING AGENTS, PLAIN |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2024-06-07 |
| Actual discontinuation date | |
| Remaining supply date | 2024-06-07 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 6775 FINANCIAL DRIVE MISSISSAUGA, ONTARIO CANADA L5N 0A4 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2024-03-26 | French | Compare |
| v3 | 2024-03-26 | English | Compare |
| v2 | 2024-03-26 | French | Compare |
| v1 | 2024-03-26 | English | Compare |
Showing 1 to 4 of 4